This site requires JavaScript to be enabled to work properly. Please modify your settings or use a different browser to continue


Leaving GSK Pro

You are leaving GSK Pro to visit a separate website not associated with GSK Pro, a portal for US Healthcare Professionals.There are website links to third-party sites on GSK Pro. GSK is not responsible for content on third-party websites.



See the immunogenicity in infants and toddlers

Safety and effectiveness of MENVEO 1-vial presentation in children younger than 10 years have not been established.

MENVEO 2-vial presentation is the only MenACWY vaccine approved for use in infants as young as 2 months of age1,2,3

Most infants and toddlers who completed the 4-dose series had a protective immune response with MENVEO 2-vial presentation1

  • The primary endpoint for MENVEO 2-vial presentation (adequacy of immune response) was met following the full 4-dose series, given at 2, 4, 6, and 12 months of age*

Bactericidal Antibody Response Rates Post-dose 3 and Post-dose 4 in Children 2 Months Through 23 Months of Age1,*

  •   *Prespecified criteria for adequacy of immune response were met (lower limit of the 95% CI ≥80% for serogroup A and ≥85% for serogroups C, W, and Y).1

Geometric mean titers (GMTs) are a measure of the level of immune response to a vaccine in a specific study group. Infants and toddlers vaccinated with MENVEO 2-vial presentation were found to have circulating bactericidal antibodies to MenACWY following the full 4-dose series.

GMTs Post-dose 3 and Post-dose 4 in Children 2 Months Through 23 Months of Age1,

CI=confidence interval; MenACWY=meningococcal serogroups A, C, W, Y; MMRV=measles, mumps, rubella, varicella; hSBA=human serum bactericidal assay.

  •   hSBA GMTs at 1-month post-dose 3 and 1-month post-dose 4 of MENVEO with routine infant/toddler vaccines.1

Randomized, controlled, multicenter study of infants initiating vaccination at 2 months of age with either MENVEO 2-vial presentation concomitantly with routine infant vaccines (diphtheria toxoid, tetanus toxoid, and acellular pertussis, inactivated poliovirus types 1, 2, and 3, hepatitis B, Haemophilus influenzae type b, pentavalent rotavirus, and 7-valent pneumococcal conjugate [PCV7]) or routine infant vaccines alone. Toddlers received the fourth dose of MENVEO 2-vial presentation concomitantly with PCV7, MMRV (measles, mumps, rubella, varicella), and inactivated hepatitis A vaccines.1


  1. Prescribing Information for MENVEO.
  2. Prescribing Information for Menactra.
  3. Prescribing Information for MenQuadfi.


MENVEO is a vaccine indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135 in individuals 2 months through 55 years of age. MENVEO does not prevent N. meningitidis serogroup B infections.


  • Do not administer MENVEO to individuals with a severe allergic reaction (eg, anaphylaxis) to a previous dose of MENVEO, to any component of this vaccine, or to any other diphtheria toxoid-containing vaccine
  • Appropriate medical treatment must be available should an acute allergic reaction, including an anaphylactic reaction, occur following administration of MENVEO
  • Syncope (fainting) has occurred in association with administration of MENVEO. Procedures should be in place to avoid injury from fainting
  • Some individuals with altered immunocompetence, including some individuals receiving immunosuppressant therapy, may have reduced immune responses to MENVEO
  • Individuals with certain complement deficiencies and individuals receiving treatment that inhibits terminal complement activation (for example, eculizumab) are at increased risk for invasive disease caused by Neisseria meningitidis serogroups A, C, Y, and W, even if they develop antibodies following vaccination with MENVEO
  • Guillain-Barré syndrome (GBS) has been reported in temporal relationship following administration of another US-licensed meningococcal quadrivalent polysaccharide conjugate vaccine. The decision to administer MENVEO to individuals with a history of GBS should take into account the expected benefits and potential risks
  • Apnea following intramuscular vaccination has been observed in some infants born prematurely. A decision about when to administer MENVEO to an infant born prematurely should be based on consideration of the individual infant’s medical status and the potential benefits and possible risks of vaccination
  • Common solicited adverse reactions among children initiating vaccination: at 2 months of age and receiving the four-dose series were tenderness and erythema at injection site, irritability, sleepiness, persistent crying, change in eating habits, vomiting, and diarrhea; at 7 months through 23 months of age and receiving the two-dose series were tenderness and erythema at injection site, irritability, sleepiness, persistent crying, change in eating habits, and diarrhea; at 2 through 10 years of age who received MENVEO were injection site pain, erythema, irritability, induration, sleepiness, malaise, and headache. Common solicited adverse reactions among adolescents and adults aged 11 through 55 years who received a single dose of MENVEO were pain at the injection site, headache, myalgia, malaise, and nausea. Across all age groups, some events were severe. Similar rates of solicited adverse reactions among adolescents and adults were observed following a single booster dose
  • In two clinical studies, there were no notable differences in frequency and severity of solicited adverse reactions in individuals who received MENVEO 1-vial presentation compared to individuals who received the 2-vial presentation
  • Vaccination with MENVEO may not result in protection in all vaccine recipients

Trademarks are property of their respective owners.